New Menopause Drug Data to Be Presented in San Diego
Clinical results for an investigational antibody treatment for hot flashes will be shared with the medical community.
Updated on Oct. 8, 2026 in Women’s Health
Live Poll
Do you trust that medical research is adequately prioritizing effective treatments for menopause symptoms?
AbCellera will present Phase 1 and Phase 2 clinical trial data for its investigational drug ABCL635 at The Menopause Society 2026 Annual Meeting in San Diego on October 22, 2026. The findings evaluate a new potential treatment option for the millions of women managing vasomotor symptoms.
Why it matters
Vasomotor symptoms like hot flashes affect up to 80% of women, with roughly 12 million in the U.S. experiencing moderate-to-severe discomfort. New therapeutic research is vital for improving quality of life for the significant portion of this population currently seeking relief.
The presentation will feature safety data from a Phase 1 multiple ascending dose study and patient-reported outcomes from a multicenter, Phase 2 randomized, double-blind, placebo-controlled trial. These preliminary findings focus on an NK3R monoclonal antibody antagonist.
The players
AbCellera
A biotechnology company headquartered in Vancouver that specializes in antibody-based drug discovery and clinical development.
The Menopause Society
A professional organization dedicated to providing evidence-based information and advancing research on the health of women during menopause.
The details
ABCL635 is designed to function as an NK3R monoclonal antibody antagonist. By targeting KNDy neurons located on the hypothalamus, the medication aims to modulate the pathways that regulate body temperature. This mechanism is intended to help reduce the frequency and severity of vasomotor symptoms in menopausal women.
Timeline
The Menopause Society 2026 Annual Meeting will take place from October 20 to 24, 2026.
The presentation regarding ABCL635 is scheduled for October 22, 2026, at 6:15 p.m. PDT.
Health Landscape
The development of ABCL635 represents an ongoing expansion of non-hormonal therapeutic options for menopausal vasomotor symptoms. This research contributes to a broader shift in women's health toward targeted neurological pathways for symptom management.
This development highlights the ongoing clinical search for non-hormonal therapies for moderate-to-severe hot flashes. Patients should discuss existing treatment options and any upcoming clinical research with their primary care physician or a menopause specialist.
The takeaway
ABCL635 is being studied as a potential non-hormonal treatment for the millions of women experiencing vasomotor symptoms. If you are struggling with menopausal symptoms, maintain a symptom log to share during your next visit with your physician to discuss evidence-based management strategies.
What happens next
The formal presentation of the Phase 2 clinical data will occur at the Hilton Bayfront in San Diego on October 22, 2026.
Further reading
For more on managing symptoms, see our guide to Women’s Health.
More information
Review the latest AbCellera clinical pipeline details to understand the status of this investigation.
Live Poll
Do you trust that medical research is adequately prioritizing effective treatments for menopause symptoms?
